Microarray analysis for the identification of specific proteins and functional modules involved in the process of hepatocellular carcinoma originating from cirrhotic liver

WUFENG FAN\textsuperscript{1} and GUANGMING YE\textsuperscript{2}

\textsuperscript{1}Section of Medical Affairs, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei 441000; \textsuperscript{2}Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China

Received December 7, 2016; Accepted June 30, 2017

DOI: 10.3892/mmr.2018.8555

Abstract. In order to identify the potential pathogenesis of hepatocellular carcinoma (HCC) developing from cirrhosis, a microarray-based transcriptome profile was analyzed. The GSE63898 expression profile was downloaded from the Gene Expression Omnibus database, which included data from 228 HCC tissue samples and 168 cirrhotic tissue samples. The Robust Multi-array Average in the Affy package of R was used for raw data processing and Student’s t-test was used to screen differentially expressed genes (DEGs). An enrichment analysis was then conducted using the Database for Annotation, Visualization and Integrated Discovery online tool, and the protein-protein interaction (PPI) network was constructed using the Search Tool for the Retrieval of Interacting Genes and Cytoscape. Furthermore, the MCODE plug-in of Cytoscape was used to conduct a sub-module analysis. A total of 634 DEGs were identified between HCC and cirrhosis, of which 165 were upregulated and 469 were downregulated. According to the cut-off criteria, the PPI network was constructed and Jun proto-oncogene, AP-1 transcription factor subunit (degree, 39), Fos proto-oncogene, AP-1 transcription factor subunit (degree, 34) and v-myc avian myelocytomatosis viral oncogene homolog (degree, 32) were identified as the hub nodes of the PPI network. Based on the sub-module analysis, four specific modules were identified. In particular, module 1 was significantly enriched in the chemokine signaling pathway, and C-X-C motif chemokine ligand 12, C-C motif chemokine receptor 7 (CCR7) and C-C motif chemokine ligand 5 (CCL5) were three important proteins in this module. Module 4 was significantly enriched in chemical carcinogenesis, and cytochrome P450 family 2 subfamily E member 1, cytochrome P450 family 2 subfamily C member 9 (CYP2C9) and cytochrome P450 family 2 subfamily A member 6 (CYP2A6) were three important proteins in this module. In conclusion, the present study revealed that CCR7, CCL5, CYP2C9 and CYP2A6 are novel genes identified in the development of HCC; however, the actual functions of these genes require verification.

Introduction

Hepatocellular carcinoma (HCC) is one of the most common types of malignant cancer, which is associated with a poor prognosis. In addition, HCC is the fourth most common cause of cancer-associated mortality worldwide (1). It was previously estimated that 39,230 new cases of HCC and 27,170 cases of HCC-associated mortality would occur in the United States in 2016 (1). Due to the highest occurrence of HCC in East Asia, this estimation should be further increased in this area (2). Chronic liver diseases, including hepatitis, fibrosis and cirrhosis, are the primary causes of HCC. In addition, ~90% of cases of HCC develop from cirrhotic livers (3), and HCC and cirrhosis share numerous risk factors, including hepatitis, alcohol consumption, obesity, diabetes, gender and advanced age (4,5). These findings suggest that cirrhosis and HCC may share pathophysiological similarities.

Despite the aforementioned correlations between HCC and cirrhosis, the detailed mechanisms linking these two diseases remain to be fully elucidated. Hepatic stellate cells (HSCs) are primary fibrogenic cells, which are involved in cirrhosis-dependent carcinogenesis (6). Su et al (7) indicated that HSCs can be activated by inflammatory signals and macrophages, which contribute to fibrogenesis, and therefore may be considered positive risk factors for HCC. Furthermore, it has been demonstrated that activated HSCs can foster a conducive environment to directly support hepatic tumorigenesis via secreting numerous cytokines, including Wnt ligands, interleukin 6 and growth factors (8). De Minicis et al (9) reported that HSCs can be activated by lipopolysaccharide produced by...
the intestinal microflora via the toll-like receptor 4 signaling pathway, which can upregulate the expression of proinflammatory chemokines or cytokines, and facilitate the invasion and migration of HCC (10). Increased extracellular matrix (ECM) production is another feature of cirrhosis that contributes to tumorigenesis (11). Previous studies have reported that increased ECM production may promote the growth, survival and migration of precancerous cells via integrin signaling (6,12). Furthermore, increased ECM production may disturb cell signaling by sequestering growth factors, including interleukin families, fibroblast growth factor and transforming growth factor (13). This sequestration may serve a role in the aberration of normal liver cells. However, although these existing studies have confirmed that the development of HCC is closely associated with cirrhosis, the detailed mechanisms remain to be elucidated. Therefore, further investigations into how HCC develops from cirrhosis are required.

In order to identify the epigenetic alterations and potential role of DNA methylation markers in HCC and its prognosis, Villanueva et al (14) generated a methylation-based prognostic signature based on 304 samples from patients with HCC after surgical resection using a training-validation scheme. The GSE63898 dataset contains data from this study, which analyzed whole-genome transcriptome alterations (14). Villanueva et al (14) confirmed a high prevalence of methylation deregulated genes, including Ras association domain family member 1, APC, WNT signaling pathway regulator and insulin like growth factor 2 (IGF2), and identified potential epidrivers, such as ephrin B2 and septin 9; however, the mechanisms underlying the development of HCC from cirrhosis were not determined. In order to investigate the pathogenesis of HCC, the GSE63898 dataset was used to analyze differences between HCC and cirrhotic liver tissues. The present study aimed to identify potential target molecules, which may aid HCC clinical treatment.

Materials and methods

Data acquisition. The GSE63898 expression profile (14), which contained data from HCC and liver cirrhosis samples, was downloaded from the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo/). The samples were sequenced using the Affymetrix Human Genome U219 Array [HG-U219] platform. In this profile, a total of 396 liver tissue samples were collected, including 228 HCC tissue samples and 168 non-tumor liver adjacent cirrhotic tissue samples. The research was authorized by the Institutional Review Boards of the participating centers.

Data preprocessing. The downloaded raw data were preprocessed using the Robust Multi-array Average method (15,16) in the Affy package of R (17), including background correction, normalization and expression calculation. Gene expression was presented as the mean value of different probes.

Differentially expressed genes (DEGs) screening. DEGs between HCC samples and cirrhotic liver samples were screened by Student's t-test in the Linear Models for Microarray Data package (18). The P-value obtained from the Student's t-test was adjusted according to the Benjamini and Hochberg method (19) and the obtained adjusted P<0.01 was set as the threshold.

Figure 1. Volcano plot of differentially expressed genes. Red dots represent upregulated genes and blue dots represent downregulated genes.

Functional and pathway enrichment analyses. Gene Ontology (GO) is a free database used in biological process (BP), molecular function and cellular component analyses (20). Kyoto Encyclopedia of Genes and Genomes (KEGG) is also a free database specifically used in pathway analysis (21). The Database for Annotation, Visualization and Integrated Discovery (DAVID) is a common online tool used in large-scale gene functional analyses (22). Therefore, GO functional and KEGG pathway enrichment analyses of DEGs were conducted using DAVID with the criterion of P<0.05.

Protein-protein interaction (PPI) network construction and analysis. According to the required confidence threshold set (combined score) >0.7, PPIs were analyzed using Search Tool for the Retrieval of Interacting Genes (23) and the PPI network was constructed by Cytoscape (24). CytoNCA (25), which is a plugin of Cytoscape for PPI network evaluation, was used to perform a topological analysis, including degree centrality (DC), betweenness centrality (BC) and closeness centrality (CC), for hub gene screening (26). Proteins were defined as nodes, and PPI associations were defined as edges in the PPI network.

Sub-module analysis. Based on the PPI network, the MCODE plugin of Cytoscape was used to screen specific bio-functional sub-modules (27) in the network. KEGG pathway analysis of these modules was performed using DAVID with the criterion of P<0.05. Proteins were defined as nodes, and PPI associations were defined as edges in modules screened from the PPI network.

Results

DEGs screening. Based on data preprocessing and Student's t-test, a total of 20,568 genes were identified, and 634 DEGs were identified between HCC samples and cirrhotic liver samples, of which 165 were upregulated and 469 were downregulated (Fig. 1).

Functional and pathway enrichment. To investigate the biological functions of the DEGs, GO_BP functional and KEGG
pathway enrichment analyses were conducted. GO_BPs of upregulated DEGs were significantly enriched in cell division \((P=2.91 \times 10^{-10})\), mitotic cell cycle \((P=5.57 \times 10^{-10})\) and mitotic nuclear division \((P=1.42 \times 10^{-7})\), etc. (Fig. 2A). Furthermore, GO_BPs of downregulated DEGs were significantly enriched in small molecule metabolic process \((P=1.87 \times 10^{-21})\), xenobiotic metabolic process \((P=7.15 \times 10^{-15})\) and immune response \((P=1.83 \times 10^{-14})\), etc. (Fig. 2B). KEGG pathways of upregulated DEGs were significantly enriched in cell cycle \((P=1.67 \times 10^{-5})\), progesterone-mediated oocyte maturation \((P=0.001)\) and p53 signaling pathway \((P=0.003)\), etc. (Fig. 2C). In addition, KEGG pathways of downregulated genes were significantly enriched in chemical carcinogenesis \((P=1.92 \times 10^{-10})\), retinol metabolism \((P=4.53 \times 10^{-8})\) and complement and coagulation cascades \((P=8.67 \times 10^{-8})\), etc. (Fig. 2D).

**PPI network analysis.** With required confidence >0.7, the PPI network for DEGs was constructed with 324 nodes and 915 edges (Fig. 3, Table I), including 74 upregulated genes and 250 downregulated genes. Downregulated Jun proto-oncogene, AP-1 transcription factor subunit (JUN; degree, 39), Fos proto-oncogene, AP-1 transcription factor subunit (FOS; degree, 34) and v-myc avian myelocytomatosis viral oncogene homolog (MYC; degree, 32) had high degrees and were therefore identified as the hub nodes in the PPI network.

**Sub-module analysis.** According to the selection criteria, four sub-modules were screened and named module 1, 2, 3 and 4 (Table II). In module 1 (Fig. 4A), there were 14 nodes with 91 edges, and according to the KEGG pathway analysis, the genes were significantly enriched in chemokine signaling pathway \((P=3.14 \times 10^{-13})\) and cytokine-cytokine receptor interaction \((P=5.07 \times 10^{-7})\), etc. In particular, downregulated C-X-C motif chemokine ligand 12 (CXCL12; degree, 13), C-C motif chemokine receptor 7 (CCR7; degree, 13) and C-C motif chemokine ligand 5 (CCL5; degree, 13) were the three nodes with the highest degrees in this module. In addition, there were 7 nodes with 21 edges identified in module 2 (Fig. 4B), and according to the KEGG pathway analysis, the genes were significantly enriched in complement and coagulation cascades \((P=5.85 \times 10^{-4})\) and p53 signaling pathway \((P=0.04)\). In particular, downregulated IGF1 (degree, 6), plasminogen (degree, 6) and...
IGF2 (degree, 6) were the three nodes with the highest degrees in this module. In module 3, there were 7 nodes with 20 edges (Fig. 4C), and according to the KEGG pathway analysis, the genes were significantly enriched in retinol metabolism ($P=5.57 \times 10^{-13}$) and steroid hormone biosynthesis ($P=1.11 \times 10^{-5}$), etc. In particular, downregulated cytochrome P450 family 1 subfamily A member 2 (degree, 6), cytochrome P450 family 4 subfamily A member 11 (degree, 6) and cytochrome P450 family 3 subfamily A member 4 (degree, 6) were the three nodes with the highest degrees in this module. In addition, there were 9 nodes with 24 edges in module 4 (Fig. 4D), and according to the KEGG pathway analysis, the genes were significantly enriched in chemical carcinogenesis ($P=2.31 \times 10^{-16}$) and drug metabolism cytochrome P450 ($P=8.13 \times 10^{-10}$), etc. In particular, downregulated cytochrome P450 family 2 subfamily E member 1 (CYP2E1; degree, 6), cytochrome P450 family 2 subfamily C member 9 (CYP2C9; degree, 6) and cytochrome P450 family 2 subfamily A member 6 (CYP2A6; degree, 5) were the three nodes with the highest degrees in this module.

### Discussion

Disease-specific differential gene expression reveals potential alterations associated with disease development. According to the analysis criteria of the present study, a total of 634 DEGs were identified in HCC versus cirrhotic tissue samples, of which 165 were upregulated and 469 were downregulated. After GO functional and KEGG pathway enrichment analyses, a PPI network was constructed with 324 nodes and 915 edges. In particular, JUN, FOS and MYC were the hub nodes in this network. Based on the PPI network, four specific modules were identified. According to the KEGG analysis results, module 1 was significantly enriched in chemokine signaling pathway, module 2 was significantly enriched in complement and coagulation cascades, module 3 was significantly enriched in retinol metabolism, and module 4 was significantly enriched in drug metabolism cytochrome P450.

The majority of the nodes in module 1 were chemokines or their receptors, including CXCL12, CCR7 and CCL5. Chemokines are cytokines that specifically respond to proinflammatory stimuli, and are involved in the migration of immune cells to damaged organs and are associated with HCC development (28). Chemokines are small molecules that can be divided into four groups (C, CC, CXC, and CXC3C) by the motifs of their NH$_2$ terminals (29). CXCL12, also known as stromal cell-derived factor 1, is produced by HSCs, biliary epithelial cells and liver sinusoidal endothelial cells (30), and has a higher expression in cirrhotic liver tissue.
and HCC (31). It is well known that the CXCL12-CXCR4 axis serves an important role in the pathogenesis of liver diseases, including cirrhosis (32), migration (33), invasion (34) and HCC prognosis (35). However, in the present study, a significant downregulation was identified in HCC compared with in cirrhosis. Furthermore, Neve Polimeno et al (36) and Shibuta et al (37) demonstrated that the expression of CXCL12 is significantly reduced in hepatoma carcinoma cells and HCC compared with normal controls; however, the detailed mechanism of this reduction remains unclear. Therefore, it may be hypothesized that the CXCL12-CXCR4 axis serves various roles in different conditions of HCC originating from cirrhosis. CCR7 has been reported to be associated with the clinicopathological parameters of HCC (38). An in vitro study indicated that the expression of CCR7 is reduced in HCC cell lines compared with in the normal liver cell line L-02 (39). A similar result was identified in the present study; CCR7 expression was downregulated in HCC tissue samples compared with in cirrhotic tissue samples. Shi et al (40) reported that CCL1, which is exclusively expressed in non-hematopoietic stromal cells (41), may serve as a tumor suppressor by inhibiting CCR7-associated chemotaxis in HCC. Furthermore, overexpression of CCL21, the ligand of CCR7, in HCC cell lines presented a potential antitumor effect in a model of HCC (42); however, the detailed function of CCR7-CCL21 requires further investigation. CCL5 has been reported to be associated with the inflammatory cirrhosis stages in chronic liver disease (43). It has been demonstrated that CCL5 downregulation is able to inhibit the effects of the human bone marrow stromal cell line HS-5 on Huh-7 cell migration and invasion via the phosphatidylinositol 3-kinase/Akt pathway (44). These findings suggested that CCL5 may promote the migration and invasion of Huh-7 cells. In addition, Sadeghi et al (45) reported that CCL5 is upregulated in the serum of patients with HCC compared with patients with cirrhosis. Conversely, in the present study, a significant downregulation in CCL5 was detected in HCC tissue samples compared with in cirrhotic tissue. Therefore, it may be hypothesized that CCL5 expression differs between tissue and serum and in vitro and in vivo. This may be a novel opportunity for CCL5-targeted therapy.

CYPs belong to a superfamily of enzymes that serve important roles in the metabolism of procarcinogens, carcinogens and drugs (46). CYP2E1, CYP2C9 and CYP2A6 were three important CYPs identified in module 4 in the present study. CYP2E1 is often deficient in HCC cell lines (47). A significant decrease in CYP2E1 expression was identified in HCC samples compared with cirrhotic tissue samples in the present study. In addition, Kinoshita and Miyata (48) reported that CYP2E1 is significantly downregulated in HCC liver tissue. Wu et al (49) reported that CYP2E1 can be downregulated by resveratrol to attenuate diethylnitrosamine and 2-acetylaminofluorene-induced hepatocarcinogenesis in Sprague Dawley rats, thereby suggesting that CYP2E1 may have an inhibitory effect on HCC carcinogenesis. In addition, hepatitis B virus (HBV)-x protein can inhibit the expression of CYP2E1 via downregulating hepatocyte nuclear factor 4 (HNF4), resulting in the promotion of human hepatoma cell growth (48). Taken together, these results suggested that CYP2E1 may be a promising target for the drug-targeted therapy of HCC. CYP2C9 has been reported to be downregulated in HCC compared with in peri-HCC and normal control tissues (50); this result was similar to the findings of the present study. In addition, it has been reported that CYP2C9 can be suppressed by hsa-microRNA-128-3P, resulting in the invasion of HCC (51). Myung et al (52) also reported that CYP2C9 is involved in the sensitization of liver cancer stem cells to anticancer drugs via the signal transducer and activator of transcription 3 signaling pathway, particularly in advanced stages. However, the detailed mechanisms of these results remain unclear; therefore, further study is required. CYP2A6 is another important member of the CYP family that was downregulated in module 4. Similar to CYP2C9, CYP2A6 can be regulated by HNF4 and is involved in the metabolism of nitrosamines and aflatoxin B1 (53). Fushiya et al (54) reported that CYP2A6 is implicated in the metabolism of 5-fluorouracil, which is commonly used in HCC clinical chemotherapy. In addition, a previous study indicated that CYP2A6 was downregulated in HBV- and hepatitis C virus-infected livers, and in HCC (55); the present study suggested that HCC samples had a significantly lower expression of CYP2A6 compared with cirrhotic liver samples. Furthermore, a previous study reported that CYP2A6 activity was decreased in moderate or severe alcoholic liver diseases, but not in mild severe alcoholic liver disease (56). Therefore, it may be hypothesized that CYP2A6 may be negatively correlated with the stage of HCC development. Further studies are required to investigate the CYP2A6-associated functions and pathways in HCC.

Although numerous DEGs with their potential functions were identified between HCC and cirrhosis samples in an in silico analysis, there remain limitations to the present

Table I. Proteins with a degree ≥20, as determined by topological analysis of the protein-protein interaction network.

| Gene   | DC  | BC   | CC  |
|--------|-----|------|-----|
| JUN    | 39  | 17,219.9 | 0.0283 |
| FOS    | 34  | 19,632.8 | 0.0283 |
| MYC    | 32  | 8,693.0  | 0.0282 |
| EGR1   | 31  | 7,531.4  | 0.0282 |
| CDK1   | 27  | 6,022.2  | 0.0280 |
| CDKN1A | 26  | 4,038.7  | 0.0280 |
| CXCL12 | 25  | 3,844.4  | 0.0279 |
| CYP2E1 | 22  | 2,721.3  | 0.0278 |
| CYP1A2 | 22  | 4,144.9  | 0.0276 |
| IGF1   | 21  | 6,096.5  | 0.0280 |
| CCR7   | 21  | 2,227.9  | 0.0277 |
| CYP3A4 | 21  | 1550.2   | 0.0277 |
| PTGS2  | 20  | 6,968.9  | 0.0281 |
| THBS1  | 20  | 5,690.0  | 0.0281 |
| CCL5   | 20  | 3,738.3  | 0.0280 |
| ANXA1  | 20  | 634.9    | 0.0275 |
| SAA1   | 20  | 1,475.6  | 0.0275 |

DC, degree centrality; BC, betweenness centrality; CC, closeness centrality.
For example, *in silico* analysis of the obtained results revealed that numerous chemokines and cytokines were involved in HCC development; however, the involvement of the identified genes *in vitro* remains unknown. Therefore, further experimental verifications of these genes are required. Furthermore, these analyses were based on subjective criteria; therefore, some genes, which have lower degrees but important roles in HCC carcinogenesis, may have been overlooked.

**Table II. Top 5 enriched Kyoto Encyclopedia of Genes and Genomes terms obtained from the subnet module analysis.**

| Term                              | Count  | P-value       | Proteins                                                                 |
|-----------------------------------|--------|---------------|--------------------------------------------------------------------------|
| **Cluster 1**                     |        |               |                                                                          |
| Chemokine signaling pathway       | 10     | 3.14x10^{-13} | CCR7, GNA11, CXCR4, CCL21, CXCL2 ...                                    |
| Cytokine-cytokine receptor interaction | 7     | 5.07x10^{-7}  | CCR7, CXCR4, CCL21, CXCL9, CCL19 ...                                    |
| Rheumatoid arthritis              | 3      | 0.007870      | CXCL6, CCL5, CXCL12.                                                     |
| NF-κB signaling pathway           | 3      | 0.008048      | CCL21, CCL19, CXCL12                                                    |
| Leukocyte transendothelial migration | 3     | 0.014455      | GNA11, CXCR4, CXCL12                                                    |
| **Cluster 2**                     |        |               |                                                                          |
| Complement and coagulation cascades | 3     | 5.85x10^{-4}  | A2M, SERPINE1, PLG.                                                      |
| p53 signaling pathway             | 2      | 0.037772      | SERPINE1, IGF1.                                                          |
| **Cluster 3**                     |        |               |                                                                          |
| Retinol metabolism                | 7      | 5.57x10^{-13} | CYP3A4, CYP4A11, CYP2B6, UGT2B11, CYP26A1 ...                             |
| Steroid hormone biosynthesis      | 4      | 1.11x10^{-5}  | CYP3A4, UGT2B11, CYP1A2, UGT2B7.                                         |
| Chemical carcinogenesis            | 4      | 2.94x10^{-5}  | CYP3A4, UGT2B11, CYP1A2, UGT2B7.                                         |
| Metabolic pathways                | 7      | 3.00x10^{-5}  | CYP3A4, CYP4A11, CYP2B6, UGT2B11, CYP26A1 ...                             |
| Drug metabolism cytochrome P450    | 3      | 7.30x10^{-4}  | CYP3A4, CYP2B6, CYP1A2.                                                  |
| **Cluster 4**                     |        |               |                                                                          |
| Chemical carcinogenesis            | 9      | 2.31x10^{-16} | GSTA2, CYP3A7, CYP2C19, CYP2C9, CYP2C18 ...                              |
| Drug metabolism-cytochrome P450    | 6      | 8.13x10^{-10} | GSTA2, CYP2C19, CYP2C9, CYP2C8, CYP2A6 ...                                |
| Metabolism of xenobiotics by cytochrome P450 | 5 | 2.30x10^{-7} | GSTA2, CYP2C9, EPHX1, CYP2A6, CYP2E1.                                    |
| Retinol metabolism                | 5      | 4.91x10^{-7}  | CYP3A7, CYP2C9, CYP2C18, CYP2C8, CYP2A6.                                 |
| Linoleic acid metabolism           | 4      | 3.70x10^{-6}  | CYP2C19, CYP2C9, CYP2C8, CYP2E1.                                         |

**Figure 4. Subnet module analyses for differentially expressed genes in the protein-protein interaction network.** Pink nodes represent upregulated genes and blue nodes represent downregulated genes. The node size is negatively related to its degree. (A) Module 1; (B) module 2; (C) module 3; and (D) module 4.
Despite these limitations, these analytical results may provide novel insights into the mechanism of HCC originating from cirrhosis. In conclusion, the present study identified a series of DEGs between HCC and cirrhotic tissue samples. Based on the GO and KEGG enrichment analyses of DEGs in the PPI network, chemokines, such as CXCL12, CCR7, CCL5, and cytokines, such as CYP2E1, CYP2C9, CYP2A6, were identified as two important components in the process of HCC developing from cirrhosis as they are associated with the regulation of inflammation, growth and the invasion of pre-cancerous cells in the liver; thus, they may serve crucial roles in HCC development. However, these results were derived from bioinformatics analysis; therefore, the effects of these genes in HCC in vivo require further verification.

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66: 7‑30, 2016.
2. Fan Q, He M, Deng X, Wu WK, Zhao L, Tang J, Wen G, Sun X and Liu Y: Derepression of c‑Fos caused by microRNA‑139 down‑regulation contributes to the metastasis of human hepatocellular carcinoma. Cell Biochem Funct 31: 319‑324, 2013.
3. Archambeaud I, Auble H, Nahon P, Planche L, Fallet G, Faroux R, Gournay J, Samuel D, Kury S and Fèray C: Risk factors for hepatocellular carcinoma in caucasian patients with non‑viral cirrhosis: The importance of prior obesity. Liver Int 35: 1872‑1876, 2015.
4. Saunders D, Seidel D, Allison M and Lyarztopoulos G: Systematic review: The association between obesity and hepatocellular carcinoma‑epidemiological evidence. Aliment Pharmacol Ther 31: 1051‑1063, 2010.
5. Naveau S: Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. Gastroentérologie Clin Biol 34: 629‑630, 2010.
6. Zhang DY and Friedman SL: Fibrosis‑dependent mechanisms of hepatocarcinogenesis. Hepatology 56: 769‑775, 2012.
7. Su TH, Kao JH and Liu CJ: Molecular mechanism and treatment of viral hepatitis‑related liver fibrosis. Int J Mol Sci 15: 10578‑10604, 2014.
8. Friedman SL: Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88: 125‑172, 2008.
9. De Minicis S, Seki E, Uchimani H, Kluwe J, Zhang Y, Brenner DA and Schwabe RF: Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology 132: 1937‑1946, 2007.
10. Liu WT, Jing YY, Yu GF, Han ZP, Yu DD, Fan QM, Ye F, Li R, Gao L, Zhao QD, et al: Toll like receptor 4 facilitates invasion and migration as a cancer stem cell marker in hepatocellular carcinoma. Cancer Lett 358: 136‑143, 2014.
11. Lee SK, Kim MH, Cheong JY, Cho SW, Yang SJ and Kwack K: Integrin αvβ6 polymorphisms and haplotypes in a Korean population are associated with susceptibility to chronic hepatitis C virus or hepatitis B virus. Eur J Immunol 34: 1164‑1174, 2004.
12. Cheloni J, Rivero ME, Pons ML, Vârue S, de Parga PM and Raymond E: Insights on the CXCL12/CXCR4 axis in hepatocellular carcinoma carcinogenesis. Am J Transl Res 6: 340‑352, 2014.
13. Schimanski CC, Bahre R, Gockel I, Müller A, Frerichs K, Hörner V, Teufel A, Simiantonaki N, Biesterfeld S, Wehter T, et al: Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer 95: 210‑217, 2006.
14. Shah AD, Bouchard MJ and Shieh AC: Intestinal fluid flow increases hepatocellular carcinoma cell invasion through CXCR4/CXCL12 and MEK/ERK signaling. PLoS One 10: e0142337, 2015.
15. Xiang ZL, Zeng ZC, Tang ZY, Fan J, Zhuang PY, Liang Y, Tan YS and He J: Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival. BMC Cancer 9: 176, 2009.
16. Neve Polimeni M, Ierano C, D’Alterio C, Simiantonaki N, Biesterfeld S, Wehter T, et al: Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer 95: 210‑217, 2006.

Molecular Medicine Reports 17: 5619‑5626, 2018
39. Luo KQ, Shi YN and Peng JC: The effect of chemokine CC motif ligand 19 on the proliferation and migration of hepatocellular carcinoma. Tumour Biol 35: 12575-12581, 2014.

40. Shi JY, Yang LX, Wang ZC, Wang LY, Zhou J, Wang XY, Shi GM, Ding ZB, Ke AW, Dai Z, et al: CC chemokine receptor like 1 functions as a tumor suppressor by impairing CCR7-related chemotaxis in hepatocellular carcinoma. J Pathol 235: 546-558, 2015.

41. Heinzel K, Benz C and Bleul CC: A silent chemokine receptor regulates steady-state leukocyte homing in vivo. Proc Natl Acad Sci USA 104: 8421-8426, 2007.

42. Liang CM, Chen L, Hu H, Ma HY, Gao LL, Qin J and Zhong CP: Chemokines and their receptors play important roles in the development of hepatocellular carcinoma. World J Hepatol 7: 1390-1402, 2015.

43. Mohs A, Kutkat N, Reißing J, Zimmermann HW, Sonntag R, Proudfoot A, Youssef SA, de Bruin A4, Cubero FJ and Trautwein C: Functional role of CCL5/RANTES for HCC progression during chronic liver disease. J Hepatol 66: 743-753, 2017.

44. Bai H, Weng Y, Bai S, Jiang Y, Li B, He F, Zhang R, Yan S, Deng F, Wang J and Shi Q: CCL5 secreted from bone marrow stromal cells stimulates the migration and invasion of Huh7 hepatocellular carcinoma cells via the PI3K-Akt pathway. Int J Oncol 45: 333-343, 2014.

45. Sadeghi M, Lahdou I, Oweira H, Daniel V, Terness P, Schmidt J, Weiss KH, Longerich T, Schemmer P, Mehrabi A: Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma. Br J Cancer 113: 756-762, 2015.

46. Korokbokova EA: Effect of natural polyphenols on CYP metabolism: Implications for diseases. Chem Res Toxicol 28: 1359-1390, 2015.

47. Puszyk WM, Hlady R, Robertson K, Cabrera R and Liu C: Epigenetic signatures of alcohol abuse in hepatocellular carcinoma. FASEB J 30 (1 Suppl): S516.11, 2016.

48. Kinoshita M and Miyata M: Underexpression of mRNA in human hepatocellular carcinoma focusing on eight loci. Hepatology 36: 433-438, 2002.

49. Wu X, Li C, Xing G, Qi X and Ren J: Resveratrol downregulates Cyp2e1 and attenuates chemically induced hepatocarcinogenesis in SD rats. J Toxicol Pathol 26: 385-392, 2013.

50. Chen H, Shen ZY, Xu W, Fan FY, Li J, Lu YF, Cheng ML and Liu J: Expression of P450 and nuclear receptors in normal and end-stage Chinese livers. World J Gastroenterol 20: 8681-8690, 2014.

51. Yu D, Green B, Marrone A, Guo Y, Kaulitcz S, Lin D, Fuscoe J, Pogribny I and Ning B: Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma. Sci Rep 5: 8534, 2015.

52. Myung SJ, Yoon JH and Yu SJ: STAT3 & Cytochrome P450 2C9: A novel signaling pathway in liver cancer stem cells. Biomed Pharmacotherapy 66: 612-616, 2012.

53. Jover R, Bort R, Gómez-Lechón MJ and Castell JV: Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: A study using adenovirus-mediated antisense targeting. Hepatology 33: 668-675, 2001.

54. Fushiya N, Takagi I, Nishino H, Akizuki S and Ohnishi A: Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. Anticancer Drugs 24: 617-622, 2013.

55. Izuka N, Oka M, Hamamoto Y, Mori N, Tamesa T, Tanguo A, Miyamoto T, Uchimura S, Tamesa T, Tanguo A, et al: Altered levels of cytochrome p450 genes in hepatitis B or C virus-infected liver identified by oligonucleotide microarray. Cancer Genomics Proteomics 1: 53-58, 2004.

56. Sotaniemi EA, Rautio A, Bäckstrom M, Arvela P and Pelkonen O: CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. Br J Clin Pharmacol 39: 71-76, 1995.